Back to search results

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Abroad (travel likely)RecruitingPHASE2

Conditions

Acute Lymphoblastic Leukemia · Measurable Residual Disease (MRD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hospital Universitario Dr. Jose E. Gonzalez, Monterrey, Nuevo León, Mexico

    Contact: Study coordinator (Andres Gomez De Leon, Professor of Hematology) · drgomezdeleon@gmail.com · +528116089404
    Contact: Study coordinator (David Gomez-Almaguer, Head of Hematology Service) · dgomezalmaguer@gmail.com · +528182593389
    Contact: Principal Investigator (Andres Gomez De Leon, Proffesor of Hematology)
    David Gomez Almaguer, Head of Hematology Service (Sub-investigator)
    Luis P. Ugarte Pelaez, Fellow of Hematology (Sub-investigator)
    Francisco J Rubio Macias, Fellow of Hematology (Sub-investigator)
View source on ClinicalTrials.gov(opens in a new tab)